LTLukasz Taraszkiewicz

Lukasz Taraszkiewicz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lukasz Taraszkiewicz has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mapping population-based cancer registries in Europe: coverage, data availability, and capacity for real-world data generation

    by V. Zadnik, A. Duratović Konjević, M. Jurtela, K. Lokar, N. Bric, T. Zagar, D. Petrova, M.J. Bento, Chirlaque, D. Coza, et al.

  • Open Access

    Changing Burden of Haematolymphoid Tumours in AYA in Poland: Organizational Challenges for the Healthcare System (Current Status and Future Perspectives)

    by Lukasz Taraszkiewicz, Patryk Włodarczyk, Michał Nocek, Maciej Trojanowski, Patrycja Filipek, Urszula Wojciechowska, Joanna A. Didkowska

    Background/Objectives: Hematological malignancies (HMs) are an important component of the cancer burden in adolescents and young adults (AYA, 15–39 years), requiring long-term specialized care. In Poland, recent healthcare reforms under the National Oncology Network (KSO) have not formally included haemato-oncology or AYA-specific needs. Methods: A population-based study was conducted using data from the Polish National Cancer Registry. AYAs diagnosed with HM between 2000 and 2022 were included. Descriptive analyses and projections were based on cases diagnosed between 2000 and 2022, whereas age-specific incidence trend analyses were restricted to the 2015–2022 period. Tumours were classified according to the HAEMCARE framework. Age-standardized incidence rates (ASIRs), annual percentage changes (APCs), and short-term projections through 2028 were estimated using generalized linear models. Additionally, data from the National Health Fund (NFZ) were analyzed to assess the geographical distribution of reimbursed drug programmes dedicated to selected HMs. Results: A total of approximately 23,000 AYA patients diagnosed with HMs were identified. Hodgkin lymphomas (HL) were the predominant tumour type across all age groups, while lymphoblastic leukemia/lymphoma was most common among younger AYAs and diffuse large B-cell lymphoma (DLBCL) increased in relative importance with age. Between 2015 and 2022, ASIRs remained stable only in two age groups (20–24 and 25–29), whereas statistically significant increases were observed among individuals aged 15–19, 30–34 and 35–39 years. Despite largely stable incidence patterns, projections indicated a growing absolute number of cases for DLBCL and follicular lymphomas. Analysis of NFZ data revealed substantial regional variation in the availability of reimbursed drug programmes, with up to six-fold differences in facility density between voivodships. Conclusions: HM epidemiology among AYAs in Poland is characterized by increasing incidence in selected lymphoma subtypes alongside declining mortality. Incorporating haemato-oncology and AYA-specific needs into national cancer planning frameworks should therefore be considered essential for future healthcare system preparedness.

  • Open Access

    Mapping evidence and gaps in diagnostic characteristics of endometrial carcinomas of the uterine corpus: implications for the WHO Classification of tumours, research, and clinical practice

    by Kateryna Maslova, Magdalena Kowalewska, Paulina Kober, Lukasz Taraszkiewicz, Maria Sromek, Mariusz Kulinczak, Richard Colling, Fiona Campbell, Alex Inskip, Stefan Holdenrieder, et al.

    Objective The project “Mapping the Evidence for the World Health Organization (WHO) Classification of Tumours: a Living Evidence Gap Map by Tumour Type, WCT EVI MAP” pioneered use of Evidence Gap Maps (EGMs) in pathology to support future WHO Tumour Classification (WCT) editions. In this study, we generated an EGM for endometrial carcinomas of the uterine corpus (ECUC). Methods Structured PubMed and Ovid Embase searches and title and abstract screening identified peer-reviewed primary studies and systematic reviews addressing diagnostic characteristics, pathogenesis, diagnostic imaging, histopathology including cytopathology, diagnostic molecular pathology, prognosis, and prediction of therapy response for endometrioid, serous, clear cell, undifferentiated/dedifferentiated, mixed, and other endometrial carcinomas, and carcinosarcomas of the uterine corpus published between 01/01/2020 and 27/08/2024. Eligible abstracts reported sufficient methodological detail and effect measures disaggregated by WCT-aligned tumour type. Purely preclinical, qualitative, in silico, omics database-derived, treatment-effectiveness, and relapse/recurrence/metastasis studies were excluded. Included studies were coded by tumour characteristics, tumour types, and study design-related evidence levels according to a predefined hierarchy (1–highest, 5–lowest). Results Of 11,165 screened studies, 698 were included, yielding 1,134 map entries. Histopathology was most frequently investigated (44.4%), followed by prognosis (29.5%), whereas prediction studies were rare (0.8%). Level 1–2 evidence was concentrated in prognosis (60.3%), while other domains were mainly supported by level ≤ 3 evidence. Systematic reviews represented 0.7% of included studies, and 70% focused on prognosis. Conclusions Histopathology is the best-supported ECUC characteristic. Evidence on treatment-response prediction remains limited, even for endometrioid carcinomas. For non-endometrioid ECUC, evidence on pathogenesis and diagnostic imaging is sparse, and molecular pathology studies are more common but mostly low-level. Major synthesis gaps remain, with systematic reviews largely restricted to prognosis. High-level primary studies and systematic reviews are needed, particularly for pathogenesis, diagnostic imaging, predictive biomarkers, and rare ECUC subtypes, to inform WCT updates and improve diagnosis.


  • Open Access

    A Narrative Review of European Registries for Skin Cancer: Where Are We and Where Should We Be?

    by Alexander Katalinic, Karima Hammas, Lukasz Taraszkiewicz, Marieke Louwman, Joanna Julia Bartnicka, Giorgia Randi, Manola Bettio, Andreas Stang, Emanuele Crocetti

    Background: European population-based cancer registries (PBCRs) provide the foundation for monitoring skin cancer, yet registration practices and coverage vary, particularly for non-melanoma skin cancer (NMSC). Methods: We conducted a narrative review combining descriptive analyses of European Cancer Information System (ECIS) outputs with evidence from the European Network of Cancer Registries (ENCR) Working Group on NMSC and from national reports. A targeted PubMed search (2015–2025) assessed scientific usage of European registry data. Results: Nearly 200 PBCRs operate across about 40 European countries, with heterogeneous structures and timeliness. The ECIS estimated 101,500 incident cutaneous melanomas (CM) in the European Union in 2022. Long-term data from Nordic countries show a tenfold increase in CM incidence over the last six decades, with recent plateauing in younger cohorts. NMSC registration remains inconsistent: some countries record both cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), others record cSCC only, and several omit NMSC entirely. Consequently, Europe-wide NMSC figures are not available from the ECIS. Global estimates exclude BCC and understate the true burden, which is likely between 1 and 1.6 million incident cases annually in Europe. The PubMed search identified 538 European registry-based publications on skin cancer (2015–2025). Conclusions: Melanoma registration in Europe is robust, but NMSC remains under-registered. Priorities include harmonized definitions and counting rules, better integration of outpatient and pathology data, streamlined EU-level reporting, digital/AI-enabled case ascertainment, and sentinel regions to generate reliable NMSC estimates.


  • Open Access

    Tumour markers and evidence-based pathology

    by Kateryna Maslova, Magdalena Chechlinska, Irmina Maria Michalek, Lukasz Taraszkiewicz, Paulina Kober, Inga Trulson, Karolina Worf, Sophie Gabriel, Laura Knoblauch, Fiona Campbell, et al.

    Background: Tumour biomarkers have become increasingly important in oncology, shaping cancer diagnostics, classification, and patient management. Despite their potential, the use of cancer biomarkers in clinical settings remains limited. Objective: This paper aims to outline biomarker development, from classical, serum protein markers to emerging tumour biomarkers, including meta-biomarkers, to show their diversity and point out the challenges in their development, reporting, and implementation in clinical practice as well as their relevance in evidence-based pathology and cancer classification. Methods: A literature-based analysis, incorporating insights from our ongoing research, is presented. Results: Although numerous potential biomarkers, biomarker signatures, and meta-biomarkers, are being discovered, existing innovations are often not supported by sufficiently rigorous research methodologies and standardised reporting practices to enable their translation into clinical practice. Conclusions: To ensure that biomarker discoveries are both scientifically sound and clinically useful, improved research and validation methods, along with adherence to established reporting standards, are essential. We propose the use of the Hierarchy of Evidence for Tumour Pathology as a framework to evaluate and map existing evidence and identify knowledge gaps and research priorities.


  • Open Access

    Advancing clinical staging in invasive breast carcinoma: the role of contrast-enhanced mammography

    by Piotr Radomyski, Maciej Trojanowski, Karolina Kijewska, Agnieszka Lis, Joanna Pietkiewicz, Krzysztof Matuszewski, Miroslawa Mocydlarz-Adamcewicz, Łukasz Taraszkiewicz, Witold Kycler

    Purpose: This study compares breast carcinoma (BC) clinical tumour staging by contrast-enhanced mammography (CEM), full-field digital mammography (FFDM), and ultrasound (US). Clinical staging is essential for multidisciplinary teams to develop optimal treatment plans and for cancer registries to generate accurate analyses of cancer epide­miology.Material and methods: Data on tumour size and the presence of multiplicity were extracted from radiology reports. Primary tumour staging (cT category) was established for each imaging modality. Enrolled cases (n = 78, adult females) had FFDM and US performed up to a month prior to CEM. Fisher’s exact test was used to examine the relationship between cT stage determination and diagnostic methods.Results: Tumour size was largest in CEM (median 47 mm), followed by FFDM (median 33 mm), and smallest in US (median 23 mm). There were statistically significant differences in the distribution of cT categories between the 3 imaging modalities, with cT2 and cT1 being most common in US (46% and 41%, respectively) and FFDM (53% and 19%, respectively). Staging by CEM followed a different pattern, with cT2 and cT3 being most common (both 38%). The multiplicity rate was equal for CEM and US (42%), with fewer cases in FFDM (13%).Conclusions: The tumour size measured by CEM is greater compared to measurements obtained through US and FFDM. Given the strong correlation between CEM and histopathology reported in the literature, CEM enhances the accuracy of local tumour staging in BC, thereby minimising the risk of understaging.


  • Advancing cancer data collection: ICD-11 implementation in European oncology and cancer registries

    by Maciej Trojanowski, Irmina Maria Michalek, Anna Kubiak, Łukasz Taraszkiewicz, Witold Kycler